CFTR and cystic fibrosis: Recently, we demonstrated that the current approach may be used in pre-clinical assessment of therapeutic compounds efficacy directly on native tissues [43] and similarly it may be used to identify CF patients (and CFTR mutations) who will respond to innovative therapeutic strategies, namely those aimed at increasing the residual CFTR activity and already approved for clinical use for other mutations towards a predictive personalized-medicine approach [18], [43]–[47].